Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00916058 · OUTCOME

Overall Survival at 3 Years (Phase 2)

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma · Source last updated 2019-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Percentage of participants alive
Interval / dispersion
95% Confidence Interval
Time frame
From Day 0 until time of death, assessed up to 3 years.

What was measured

Time elapsed between Day 0 and death from any cause, whichever came first, assessed up to 3 years.

Analysis population: Phase 2 includes all patients treated on phase 2 of the study (28 patients), and patients treated at Dose Level 6 of the Phase 1 portion of the study (7 patients). The dose level used during Phase 2 was Dose Level 6.

Groups in this outcome

Phase 2

Bendamustine 225 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 235

Reported measurements

Source class 1
Values in Percentage of participants alive · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase 288Not reported7295Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        72
        upper Limit
        95
        value
        88
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
Time elapsed between Day 0 and death from any cause, whichever came first, assessed up to 3 years.
dispersion Type
95% Confidence Interval
groups
  1. description
    Bendamustine 225 mg/m\^2 total, Melphalan 200 mg/m\^2 total (140 mg/m\^2 total for patients with Creatinine Clearance \<70 ml/min)
    id
    OG000
    title
    Phase 2
param Type
MEDIAN
population Description
Phase 2 includes all patients treated on phase 2 of the study (28 patients), and patients treated at Dose Level 6 of the Phase 1 portion of the study (7 patients). The dose level used during Phase 2 was Dose Level 6.
reporting Status
POSTED
time Frame
From Day 0 until time of death, assessed up to 3 years.
title
Overall Survival at 3 Years (Phase 2)
type
SECONDARY
unit Of Measure
Percentage of participants alive

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice